Stay updated on Pyrotinib Combo in HR+/HER2- Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Combo in HR+/HER2- Clinical Trial page.

Latest updates to the Pyrotinib Combo in HR+/HER2- Clinical Trial page
- CheckyesterdayChange DetectedAdded Revision: v3.4.2 to the record history. The previous government funding notice (Revision: v3.4.1) was removed.SummaryDifference0.9%

- Check8 days agoChange DetectedA general site-wide notice about government funding and NIH Clinical Center status was added. The page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.9%

- Check15 days agoChange DetectedUI changes add a Show glossary option and green/red color-coded highlights for additions and deletions, with an updated Revision label (v3.4.0). The No FEAR Act data entry was removed.SummaryDifference1%

- Check29 days agoChange DetectedThe study history shows a new revision (v3.3.4) added and the previous revision (v3.3.3) removed; these are internal record-keeping updates to the record. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check36 days agoChange DetectedVersion 2026-01-02 added core sections to the study record—Outcome Measures, Study Description, Oversight, and Study Status—representing substantive updates to the trial's documentation. The 2025-09-25 deletion indicates that prior content was removed.SummaryDifference0.8%

- Check51 days agoChange DetectedThe history now includes a new revision entry (v3.3.3) and removes the older entries for HHS Vulnerability Disclosure and revision v3.3.2.SummaryDifference0.2%

Stay in the know with updates to Pyrotinib Combo in HR+/HER2- Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Combo in HR+/HER2- Clinical Trial page.